Promoting therapeutic alliance in clozapine users: An exploratory randomized controlled trial

Clinical Schizophrenia and Related Psychoses

Volumn 3, Issue 3, 2009, Pages 127-132

  Hayward, Peter ^a   David, Anthony S ^a   Green, Nicola ^b   Rabe Hesketh, Sophia ^c   Haworth, Elke ^d   Thompson, Neil ^e   Shaffer, Sheila ^f   Hastilow, Sarah ^f   Wykes, Til ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SUSSEX PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^e LEICESTERSHIRE PARTNERSHIP NHS TRUST   (United Kingdom)

^f SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adherence; Clozapine; Cognitive behavioral therapy (CBT); Compliance; Randomized controlled trial (RCT); Schizophrenia

Indexed keywords

CLOZAPINE; PLACEBO;

ADULT; ALLIANCE ENHANCEMENT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; EMPOWERMENT; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; PSYCHOEDUCATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 70449371462     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.3.3.1     Document Type: Article

References (40)

1. Marinker M, editor. From compliance to concordance: achieving shared goals In medicine taking. London: Royal Pharmaceutical Society; Merck, Sharp, and Dohme; 1997.
2. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalisation costs associated with antipsychotic nonadherent in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23(10):2305-2312.
3. 3.AngermeyerMC,LöfflerW,MüllerP,SchulzeB,PriebeS. Patients'andrelatives'assessmentofclozapinetreatment.PsycholMed2001;31(3): 509-517.(Pubitemid32294049)
4. 4. Castle D, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients' perspective. Aust N Z J Psychiatry 2002;36(5):633-641. (Pubitemid 35174403)
5. 5.RosenheckR,ChangS,ChoeY,CramerJ,XuW,ThomasJ,etal. Medicationcontinuationandcompliance: acomparisonofpatientstreatedwithclozapineandHaloperidol.JClinPsychiatry2000; 61(5):382-386.(Pubitemid30345942)
6. 6. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32(4):715-723. (Pubitemid 44412859)
7. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al.; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-610.
8. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68(11):1751-1762.
9. 9.HayhurstKP,BrownP,LewisSW.Thecost-effectivenessofclozapine:acontrolled , population-based,mirror-imagestudy.JPsychopharmacol2002;16(2):169-175. (Pubitemid34614887)
10. 10.WhiskeyE,WykesT,Duncan-McConnelD,HaworthE,WalshN,HastilowS. Continuationofclozapinetreatment:practicemakesperfect.PsychiatricBulletin2003; 27(6):211-213.(Pubitemid36681906)
11. 11.LecompteD,PeIcI.Acognitive-behaviouralprogram- improvecompliancewithmedicationinpatientswithschizophrenia. InternationalJournalofMentalHealth1996;25(1):51-56.(Pubitemid126072977)
12. Kemp R, Hay ward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996;312(7027):345-349.
13. 13.KempR,KirovG,EverittB,HaywardP,DavidA. Randomisedcontrolledtrialofcompliancetherapy:18-monthfollow- uBrJPsychiatry1998;172:413-419.(Pubitemid28204550)
14. Maneesakorn S, Robson D, Gournay K, Gray R. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand. J Clin Nurs 2007;16(7):1302-1312.
15. Uzenoff SR, Perkins DO, Hamer RM, Wiesen CA, Penn DL. A preliminary trial of adherence-coping-education (ACE) therapy for early psychosis. J Nerv Ment Dis 2008;196(7):572-575.
16. 16.O'DonnellC,DonohoeG,SharkeyL,OwensN,MigoneM,HarriesR,etal. Compliancetherapy:arandomisedcontrolledtrialinschizophrenia.BMJ2003;327(7419): 834.(Pubitemid37271693)
17. 17.ByerlyMJ,FisherR,CarmodyT,RushAJ. Atrialofcompliancetherapyinoutpatientswithschizophreniaorschizoaffectivedisor der.JClinPsychiatry2005;66(8):997-1001.(Pubitemid41191791)
18. 18. Gray R, Leese M, Bindman J, Becker T, Burti L, David A, et al. Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry 2006:189:508-514. (Pubitemid 44876869)
19. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999:175:576-580.
20. Lecomte T, Spidel A, Ledere C, MacEwan GW, Greaves C, Bentall RP. Predictors and profiles of treatment non-adherence and engagement in services problems in early psychosis. Schizophr Res 2008;102(1-3):295-302.
21. 21. de Haan L, van Amelsvoort T, Dlngemans P, Linszen D. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a projective five year follow-up. Pharmacopsychiatry 2007;40(6):264-268. (Pubitemid 350232818)
22. 22. Buckley PF, Wirshing DA, Bhusham P, Pierre JM, Resnick SA, Wirshing WC. Lack of insight in schizophrenia: Impact on treatment adherence. CNS Drugs 2007;21(2):129-141. (Pubitemid 46247818)
23. 23. Lincoln TM, Wilhelm K, Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res 2007;96(l-3):232-245. (Pubitemid 47500142)
24. 24.RogersES,ChamberlinJ,EllisonML,CreanT.Aconsumer-constructedscale- measureempowermentamongusersofmentalhealthservices.PsychiatrServ1997;48(8): 1042-1047.(Pubitemid27329958)
25. Horvath AO, Greenberg LS. Development and validation of the Working Alliance Inventory. Journal of Consulting and Clinical Psychology 1989;36(2):223-233.
26. 26.BirchwoodM,SmithJ,DruryV,HealyJ,MacmillanF,SladeM.Aself- reportInsightScaleforpsychosis:reliability,validityandsensitivity-change. ActaPsychiatrScand1994:89(1):62-67.(Pubitemid24028268)
27. 27.HoganTP,AwadAG,EastwoodR.Aself- reportscalepredictiveofdrugcomplianceinschizophrenics: reliabilityanddiscriminativevalidity.PsycholMed1983;13(1):177-183. (Pubitemid13132147)
28. 28. Hayward P, Chan N, Kemp R, Youle S, David A. Medication self-management: a preliminary report on an intervention to improve medication compliance. Journal of Mental Health 1995;4:511-517. (Pubitemid 26009202)
29. 29.KaySR,FiszbeinA,OplerLA.Thepositiveandnegativesyndromescale(PANSS) forschizophrenia.SchizophrBull1987;13(2):261-276.(Pubitemid18039085)
30. 30.KempR,DavidA,HaywardP.Compliancetherapy: aninterventiontargetinginsightandtreatmentadherenceinpsychoticpatients. BehaviouralandCognitivePsychotherapy1996;24:331-350.(Pubitemid27060780)
31. Surguladze S, Timms P, David AS. Teaching psychiatric trainees 'compliance therapy'. Psychiatric Bulletin 2001:26:12-15.
32. Moore A, Sellwood W, Stirling J. Compliance and psychological reactance in schizophrenia. Br J Clin Psychol 2000;39 (Pt 3):287-295.
33. Rabe-Hesketh S, Skrondal A, Pickles A. Reliable generalisation of generalised linear mixed models using adaptive quadrature. The Stata Journal 2002;2:1-21.
34. Tarrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? Behav Res Ther 2004;42(12):1377-1401.
35. Kemp R, Hayward P, David A. Compliance Therapy Manual. Macclesfield (UK): Gardiner-Caldwell; 1997.
36. 36. Rathod S, Kingdon D, Smith P, Turkington D. Insight into schizophrenia: the effects of cognitive behavioural therapy on the components of insight and association with sociodemographics-data on a previously published randomised controlled trial. Schizophr Res 2005;74(2-3):211-219. (Pubitemid 40255079)
37. 37. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic regimens: associations with resource use and costs. Br J Psychiatry 2004:184:509-516. (Pubitemid 38725711)
38. 38. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-351. (Pubitemid 38491171)
39. Patel NC, Crismon ML, Miller AL, Johnsrud MT. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy 2005;25(9):1242-1247.
40. 40.CramerJA,RosenheckR. Compliancewithmedicationregimensformentalandphysicaldisorders. PsychiatrServ1998;49(2):196-201.(Pubitemid28071427)